DM
CLDX icon

Deerfield Management’s Celldex Therapeutics CLDX Stock Holding History

Deerfield Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-42,196
Closed -$2.24M – 108
2016
Q4 		$2.24M Buy
+42,196
New +$2.4M 0.09% 92

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Deerfield Management's CLDX Position: Q1 2017 in Review

Deerfield Management sold out of Celldex Therapeutics (CLDX) in Q1 2017, closing a stake of 42,196 shares — an estimated $2.24M sold.

Deerfield Management first reported a position in CLDX in Q4 2016 and held it in 1 quarter. The position peaked at $2.24M in Q4 2016. 134 funds tracked by Wall St. Rank hold CLDX as of Q1 2017.

  • Deerfield Management reported no remaining Celldex Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Deerfield Management sold 42,196 Celldex Therapeutics shares in Q1 2017, an estimated $2.24M.
  • Deerfield Management first reported a position in Celldex Therapeutics in Q4 2016 and held it in 1 quarter.
  • Deerfield Management's Celldex Therapeutics position peaked at $2.24M in Q4 2016.
  • 134 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2017.

Based on Deerfield Management's 13F filing for Q1 2017, filed 15 May 2017.